|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
US4935341A
(en)
|
1986-06-04 |
1990-06-19 |
Whitehead Institute For Biomedical Research |
Detection of point mutations in neu genes
|
|
DE3169595D1
(en)
|
1980-11-10 |
1985-05-02 |
Gersonde Klaus |
Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
JPS58118008A
(ja)
|
1982-01-06 |
1983-07-13 |
Nec Corp |
デ−タ処理装置
|
|
EP0088046B1
(de)
|
1982-02-17 |
1987-12-09 |
Ciba-Geigy Ag |
Lipide in wässriger Phase
|
|
DE3218121A1
(de)
|
1982-05-14 |
1983-11-17 |
Leskovar, Peter, Dr.-Ing., 8000 München |
Arzneimittel zur tumorbehandlung
|
|
EP0102324A3
(de)
|
1982-07-29 |
1984-11-07 |
Ciba-Geigy Ag |
Lipide und Tenside in wässriger Phase
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
DE3486459D1
(de)
|
1983-09-26 |
1997-12-11 |
Udo Dr Med Ehrenfeld |
Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
|
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
|
US7838216B1
(en)
|
1986-03-05 |
2010-11-23 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Human gene related to but distinct from EGF receptor gene
|
|
US5401638A
(en)
|
1986-06-04 |
1995-03-28 |
Oncogene Science, Inc. |
Detection and quantification of neu related proteins in the biological fluids of humans
|
|
US4968603A
(en)
|
1986-12-31 |
1990-11-06 |
The Regents Of The University Of California |
Determination of status in neoplastic disease
|
|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
US5720937A
(en)
|
1988-01-12 |
1998-02-24 |
Genentech, Inc. |
In vivo tumor detection assay
|
|
ATE130873T1
(de)
|
1988-04-18 |
1995-12-15 |
Applied Biotechnology Inc |
Nachweis der expression von neu genen und produkten.
|
|
EP0474727B1
(en)
|
1989-05-19 |
1997-07-23 |
Genentech, Inc. |
Her2 extracellular domain
|
|
US5705157A
(en)
|
1989-07-27 |
1998-01-06 |
The Trustees Of The University Of Pennsylvania |
Methods of treating cancerous cells with anti-receptor antibodies
|
|
US6884418B1
(en)
|
1989-08-04 |
2005-04-26 |
Berlex Laboratories, Inc. |
Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
|
|
DE69033842T2
(de)
|
1989-08-04 |
2002-06-20 |
Schering Ag |
Äusserliche domäne von c-erbb-2:gp75
|
|
EP0494135B1
(en)
|
1989-09-29 |
1996-04-10 |
Oncogene Science, Inc. |
Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
|
|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
AU662311B2
(en)
|
1991-02-05 |
1995-08-31 |
Novartis Ag |
Recombinant antibodies specific for a growth factor receptor
|
|
IL101943A0
(en)
|
1991-05-24 |
1992-12-30 |
Genentech Inc |
Structure,production and use of heregulin
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5939531A
(en)
|
1991-07-15 |
1999-08-17 |
Novartis Corp. |
Recombinant antibodies specific for a growth factor receptor
|
|
WO1993003741A1
(en)
|
1991-08-22 |
1993-03-04 |
Becton, Dickinson & Company |
Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
|
|
EP0604580A1
(en)
|
1991-09-19 |
1994-07-06 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
|
|
US5288477A
(en)
|
1991-09-27 |
1994-02-22 |
Becton, Dickinson And Company |
Method for prognosticating response to cancer therapy
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
AU3236793A
(en)
|
1991-12-12 |
1993-07-19 |
Berlex Laboratories, Inc. |
Recombinant and chimeric antibodies to c-erbB-2
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
AU4025193A
(en)
|
1992-04-08 |
1993-11-18 |
Cetus Oncology Corporation |
Humanized C-erbB-2 specific antibodies
|
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
|
JPH08504172A
(ja)
|
1992-06-30 |
1996-05-07 |
オンコロジクス，インコーポレイティド |
抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
|
|
WO1994009022A1
(en)
|
1992-10-09 |
1994-04-28 |
Oncor, Inc. |
Methods for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue
|
|
CA2103323A1
(en)
|
1992-11-24 |
1994-05-25 |
Gregory D. Plowman |
Her4 human receptor tyrosine kinase
|
|
PT616812E
(pt)
|
1993-03-24 |
2000-04-28 |
Berlex Biosciences |
Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro
|
|
AU6527894A
(en)
|
1993-03-30 |
1994-10-24 |
Trustees Of The University Of Pennsylvania, The |
Prevention of tumors with monoclonal antibodies against (neu)
|
|
US20030108545A1
(en)
|
1994-02-10 |
2003-06-12 |
Patricia Rockwell |
Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
|
|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
|
US5910486A
(en)
|
1994-09-06 |
1999-06-08 |
Uab Research Foundation |
Methods for modulating protein function in cells using, intracellular antibody homologues
|
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
US5846749A
(en)
|
1994-10-12 |
1998-12-08 |
The Regents Of The University Of California |
Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
|
|
US6214388B1
(en)
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
|
EP0711565B1
(en)
|
1994-11-10 |
1998-08-26 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Inhibiting growth of leukemic cells by targeting HER-2 protein
|
|
AU4289496A
(en)
|
1994-12-02 |
1996-06-19 |
Chiron Corporation |
Method of promoting an immune response with a bispecific antibody
|
|
US5783404A
(en)
|
1995-04-13 |
1998-07-21 |
Amgen Inc. |
Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
|
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
|
WO1997000271A1
(en)
|
1995-06-14 |
1997-01-03 |
The Regents Of The University Of California |
Novel high affinity human antibodies to tumor antigens
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
|
US5925519A
(en)
|
1996-06-03 |
1999-07-20 |
The Regents Of The University Of California |
Genetic alterations associated with prostate cancer
|
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
|
CN101412758A
(zh)
|
1996-10-18 |
2009-04-22 |
基因技术股份有限公司 |
抗ErbB2抗体
|
|
US6468547B1
(en)
|
1996-10-30 |
2002-10-22 |
Uab Research Foundation |
Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain secretory antibodies
|
|
WO1998018489A1
(en)
|
1996-10-30 |
1998-05-07 |
The Uab Research Foundation |
Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
|
|
ES2293661T3
(es)
|
1996-11-27 |
2008-03-16 |
Genentech, Inc. |
Purificacion por afinidad de polipeptido en una matriz de proteinas a.
|
|
EP1012275A1
(en)
|
1997-01-31 |
2000-06-28 |
University Of Rochester |
Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
|
|
US5994071A
(en)
|
1997-04-04 |
1999-11-30 |
Albany Medical College |
Assessment of prostate cancer
|
|
US20020076695A1
(en)
*
|
1997-04-04 |
2002-06-20 |
Jeffrey S. Ross |
Methods for treating prostate cancer
|
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
US6358682B1
(en)
|
1998-01-26 |
2002-03-19 |
Ventana Medical Systems, Inc. |
Method and kit for the prognostication of breast cancer
|
|
US20020192211A1
(en)
|
1998-03-17 |
2002-12-19 |
Hudziak Robert M. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
PT1064027E
(pt)
|
1998-03-27 |
2008-09-29 |
Genentech Inc |
Sinergismo de ligando de apo-2 e anticorpo anti-her-2
|
|
US7244826B1
(en)
|
1998-04-24 |
2007-07-17 |
The Regents Of The University Of California |
Internalizing ERB2 antibodies
|
|
ATE370961T1
(de)
|
1998-05-06 |
2007-09-15 |
Genentech Inc |
Reinigung von antikörpern durch ionenaustauschchromatographie
|
|
US6573043B1
(en)
|
1998-10-07 |
2003-06-03 |
Genentech, Inc. |
Tissue analysis and kits therefor
|
|
CA2357525A1
(en)
|
1999-01-27 |
2000-08-03 |
Cornell Research Foundation, Inc. |
Treating cancers associated with overexpression of her-2/neu
|
|
US6316462B1
(en)
|
1999-04-09 |
2001-11-13 |
Schering Corporation |
Methods of inducing cancer cell death and tumor regression
|
|
US6333348B1
(en)
|
1999-04-09 |
2001-12-25 |
Aventis Pharma S.A. |
Use of docetaxel for treating cancers
|
|
SI1187632T1
(sl)
|
1999-05-14 |
2009-04-30 |
Genentech Inc |
Zdravljenje z anti-ErbB2 protitelesi
|
|
JP3485252B2
(ja)
|
1999-06-16 |
2004-01-13 |
インターナショナル・ビジネス・マシーンズ・コーポレーション |
情報処理方法、情報端末支援サーバ、コラボレーション・システム、情報処理プログラムを格納する記憶媒体
|
|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
|
AR024464A1
(es)
|
1999-06-25 |
2002-10-02 |
Genentech Inc |
Anticuerpos anti-erbb2 humanizados.
|
|
DE60033658T2
(de)
|
1999-06-25 |
2007-11-22 |
Genentech, Inc., South San Francisco |
Behandlung von prostata-krebs mit anti-erbb2 antikörpern
|
|
US20030086924A1
(en)
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US20040013667A1
(en)
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
EP2977063A1
(en)
|
1999-06-25 |
2016-01-27 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
GB9917012D0
(en)
|
1999-07-20 |
1999-09-22 |
Pharmacia & Upjohn Spa |
Combined preparations comprising antitumor agents
|
|
CN1399645A
(zh)
|
1999-07-29 |
2003-02-26 |
米德列斯公司 |
Her2/neu的人单克隆抗体
|
|
EP2110138A1
(en)
|
1999-08-27 |
2009-10-21 |
Genentech, Inc. |
Dosages for treatment of anti-erbB2 antibodies
|
|
CA2383615A1
(en)
|
1999-09-22 |
2001-03-29 |
Corixa Corporation |
Methods for diagnosis and therapy of hematological and virus-associated malignancies
|
|
GB9925958D0
(en)
|
1999-11-02 |
1999-12-29 |
Bundred Nigel J |
Therapeutic use
|
|
WO2001053354A2
(en)
|
2000-01-20 |
2001-07-26 |
Chiron Corporation |
Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules
|
|
CA2397349A1
(en)
|
2000-02-29 |
2001-09-07 |
Ivan David Horak |
Farnesyl protein transferase inhibitor combinations with an her2 antibody
|
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
|
US6767541B2
(en)
|
2000-03-20 |
2004-07-27 |
The Regents Of The University Of California |
HER-2/neu overexpression abrogates growth inhibitory pathways
|
|
GB0008368D0
(en)
|
2000-04-06 |
2000-05-24 |
Astrazeneca Ab |
Combination product
|
|
CA2404919A1
(en)
|
2000-04-06 |
2002-10-01 |
Kyowa Hakko Kogyo Co. Ltd. |
Diagnostic and therapeutic agents for rheumatoid arthritis
|
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
|
HK1054200A1
(zh)
|
2000-05-15 |
2003-11-21 |
法玛西雅意大利公司 |
芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂
|
|
WO2001089566A1
(en)
|
2000-05-19 |
2001-11-29 |
Genentech, Inc. |
Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
|
|
GB0017635D0
(en)
|
2000-07-18 |
2000-09-06 |
Pharmacia & Upjohn Spa |
Antitumor combined therapy
|
|
TWI317285B
(en)
|
2000-07-28 |
2009-11-21 |
Dainippon Sumitomo Pharma Co |
New use and kit for remedies for cancer
|
|
AU2001295002B2
(en)
|
2000-08-09 |
2007-05-31 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
|
US6984494B2
(en)
|
2000-08-15 |
2006-01-10 |
Genentech, Inc. |
Analytical method
|
|
NZ546251A
(en)
|
2000-12-01 |
2008-01-31 |
Response Genetics Inc |
Method of determining epidermal growth factor receptor gene expression in a parafin embedded tiasue sample and correlation of levels thereof with survival rates
|
|
US6602670B2
(en)
|
2000-12-01 |
2003-08-05 |
Response Genetics, Inc. |
Method of determining a chemotherapeutic regimen based on ERCC1 expression
|
|
US6582919B2
(en)
|
2001-06-11 |
2003-06-24 |
Response Genetics, Inc. |
Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
|
|
US7005278B2
(en)
|
2001-03-02 |
2006-02-28 |
Danenberg Kathleen D |
Method of determining dihydropyrimidine dehydrogenase gene expression
|
|
US20020142328A1
(en)
|
2000-12-01 |
2002-10-03 |
Danenberg Kathleen D. |
Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
|
|
AU2002239486A1
(en)
|
2000-12-08 |
2002-06-18 |
Uab Research Foundation |
Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
|
|
CA2436326C
(en)
|
2001-01-09 |
2012-08-14 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
|
|
US20040138160A1
(en)
|
2001-04-27 |
2004-07-15 |
Kenichiro Naito |
Preventive/therapeutic method for cancer
|
|
AU2002315306B2
(en)
|
2001-05-08 |
2007-05-17 |
Merck Patent Gmbh |
Combination therapy using anti-EGFR antibodies and anti-hormonal agents
|
|
ITRM20010408A1
(it)
|
2001-07-10 |
2003-01-10 |
Univ Napoli Federico Ii |
Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
|
|
AU2002326531A1
(en)
|
2001-08-03 |
2003-02-17 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies to activated erbb family members and methods of use thereof
|
|
US20030068318A1
(en)
|
2001-09-28 |
2003-04-10 |
O'brien Timothy |
Treatment of uterine serous papillary cancer
|
|
US20030096823A1
(en)
|
2001-11-16 |
2003-05-22 |
Beryl Asp |
Method for the treatment of cardiotoxicity induced by antitumor compounds
|
|
US20030175845A1
(en)
|
2002-03-13 |
2003-09-18 |
Kalbag Suresh M. |
Use of sulfitolysis in high performance peptide mapping
|
|
US20030190689A1
(en)
|
2002-04-05 |
2003-10-09 |
Cell Signaling Technology,Inc. |
Molecular profiling of disease and therapeutic response using phospho-specific antibodies
|
|
AU2003221684A1
(en)
|
2002-04-08 |
2003-10-27 |
Smithkline Beecham Corporation |
Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
|
|
JP2005522514A
(ja)
|
2002-04-10 |
2005-07-28 |
ジェネンテック・インコーポレーテッド |
抗ｈｅｒ２抗体改変体
|
|
ITTO20020340A1
(it)
|
2002-04-19 |
2003-10-20 |
Biother Di Contardi Gabriella |
Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
|
|
US20030202973A1
(en)
|
2002-04-29 |
2003-10-30 |
Dr. George Pieczenik |
Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
|
|
AU2003235470A1
(en)
|
2002-06-19 |
2004-01-06 |
Smithkline Beecham Corporation |
Predictive markers in cancer therapy
|
|
HUP0600340A3
(en)
|
2002-07-15 |
2011-06-28 |
Genentech Inc |
Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
|
|
US20040013297A1
(en)
|
2002-07-18 |
2004-01-22 |
Roger Lo |
Method for performing color gamut compression
|
|
PT1543038T
(pt)
|
2002-09-11 |
2017-07-07 |
Genentech Inc |
Purificação de proteína
|
|
EP1572972A4
(en)
|
2002-11-21 |
2007-11-21 |
Genentech Inc |
THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES
|
|
WO2004053497A2
(en)
|
2002-12-11 |
2004-06-24 |
Ventana Medical Systems, Inc. |
Method for predicting the response to her2-directed therapy
|
|
EP1597558A2
(en)
|
2003-01-08 |
2005-11-23 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
|
US20040231909A1
(en)
|
2003-01-15 |
2004-11-25 |
Tai-Yang Luh |
Motorized vehicle having forward and backward differential structure
|
|
JP5422120B2
(ja)
|
2004-05-27 |
2014-02-19 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト |
癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法
|
|
UA90480C2
(uk)
|
2004-07-22 |
2010-05-11 |
Джэнэнтэк, Инк. |
Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
|
|
DK1907000T4
(da)
*
|
2005-06-08 |
2020-03-30 |
The President And Fellows Of Harvard College |
Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
|
|
JP4616237B2
(ja)
|
2006-11-07 |
2011-01-19 |
日本電信電話株式会社 |
シリコン化合物薄膜の形成方法
|
|
CA2673870A1
(en)
*
|
2006-12-27 |
2008-07-10 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
WO2009089149A1
(en)
|
2008-01-03 |
2009-07-16 |
The Johns Hopkins University |
B7-h1 (cd274) antagonists induce apoptosis of tumor cells
|
|
NZ587706A
(en)
*
|
2008-03-18 |
2012-12-21 |
Genentech Inc |
Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
|
MX356367B
(es)
*
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
EP2504028A4
(en)
*
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
US8993524B2
(en)
*
|
2010-03-05 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
EP3578657B1
(en)
*
|
2010-04-06 |
2024-03-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of cd274/pd-l1 gene
|
|
CA2832387A1
(en)
*
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|